| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Leucanthoside targets tyrosinase, the key enzyme in melanin biosynthesis. It inhibits tyrosinase activity by forming multiple hydrogen bonds and hydrophobic interactions with the tyrosinase binding pocket, with an IC₅₀ of 43.47 μM. The compound also exhibits antimicrobial and antioxidative activities, suggesting additional mechanisms of action. As a triterpenoid saponin, it may also interact with cell membranes and modulate immune responses.
|
|---|---|
| ln Vitro |
In vitro, leucanthoside inhibits tyrosinase with an IC₅₀ of 43.47 μM. It shows antimicrobial and antioxidative activities. The compound's cytotoxic and immunomodulatory properties suggest potential activity against cancer cells and immune modulation. Detailed IC₅₀ values for antimicrobial and cytotoxic activities are not extensively reported in the available literature.
|
| ln Vivo |
Detailed in vivo activity data for leucanthoside are not extensively reported in the available literature. As a natural product with tyrosinase inhibitory, antimicrobial, and antioxidative activities, it is expected to have potential for in vivo efficacy in skin pigmentation disorders, infections, and oxidative stress-related conditions. However, specific in vivo efficacy data from animal studies are not provided in the available sources.
|
| Enzyme Assay |
Non-cell-based enzyme assays for leucanthoside typically involve tyrosinase inhibition assays using purified mushroom tyrosinase. The enzyme is incubated with a substrate (e.g., L-DOPA or tyrosine) and varying concentrations of leucanthoside. Tyrosinase activity is measured by monitoring the oxidation of the substrate spectrophotometrically at 475 nm. IC₅₀ values are determined from dose-response curves. Antioxidant activity can be assessed using DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays for leucanthoside are performed using melanocytes to assess inhibition of melanin production. Cells are treated with the compound at various concentrations, and melanin content is measured spectrophotometrically. Tyrosinase activity in cell lysates is assessed by measuring the oxidation of L-DOPA. Cell viability is assessed to distinguish anti-melanogenic effects from cytotoxicity. Antimicrobial activity is assessed using standard broth microdilution methods.
|
| Animal Protocol |
In vivo animal models for leucanthoside would be required to assess its therapeutic potential. Based on its mechanism as a tyrosinase inhibitor, relevant models could include mouse models of skin pigmentation, such as UV-induced pigmentation or melanin deposition models. The compound would be administered topically or systemically, and pigmentation changes would be assessed visually or by measuring melanin content in skin biopsies.
|
| ADME/Pharmacokinetics |
Leucanthoside has a molecular weight of 462.12 g/mol and a molecular formula of C₂₂H₂₂O₁₁. CAS number is 6980-25-2. The compound is soluble in DMSO. Appearance is a light yellow to yellow solid powder. Purity is >98%. Storage conditions: powder at -20°C. Detailed PK parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for leucanthoside are not extensively reported in the available literature. As a naturally occurring compound, it is generally considered to have a good safety profile, but thorough toxicological studies would be required for therapeutic development. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
According to reports, swertiamarin is found in Japanese swertiamarin, pseudo-Chinese swertiamarin, and other organisms with available data.
Leucanthoside is also known as Swertiajaponin. It is a flavone C-glycoside, structurally defined as 6-β-D-glucopyranosyl-3′,4′,5-trihydroxy-7-methoxyflavone—the 7-O-methyl ether of isoorientin. The compound inhibits tyrosinase with an IC₅₀ of 43.47 μM and shows antimicrobial and antioxidative activities. It is a triterpenoid saponin with cytotoxic and immunomodulatory properties. Leucanthoside is used in research applications studying melanogenesis, antimicrobial activity, and oxidative stress. It is for research use only. |
| Molecular Formula |
C22H22O11
|
|---|---|
| Molecular Weight |
462.4035
|
| Exact Mass |
462.116
|
| CAS # |
6980-25-2
|
| PubChem CID |
442659
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
761.3±60.0 °C at 760 mmHg
|
| Flash Point |
266.6±26.4 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.717
|
| LogP |
1.83
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
744
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
DLVLXOYLQKCAME-DGHBBABESA-N
|
| InChi Code |
InChI=1S/C22H22O11/c1-31-13-6-14-16(11(26)5-12(32-14)8-2-3-9(24)10(25)4-8)19(28)17(13)22-21(30)20(29)18(27)15(7-23)33-22/h2-6,15,18,20-25,27-30H,7H2,1H3/t15-,18-,20+,21-,22+/m1/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~540.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1626 mL | 10.8131 mL | 21.6263 mL | |
| 5 mM | 0.4325 mL | 2.1626 mL | 4.3253 mL | |
| 10 mM | 0.2163 mL | 1.0813 mL | 2.1626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
